Illuminating the structure and function of CACNG5 and 7
Project Number1R03TR004196-01
Contact PI/Project LeaderNAKAGAWA, TERUNAGA
Awardee OrganizationVANDERBILT UNIVERSITY
Description
Abstract Text
Project Summary
The majority of excitatory synaptic transmission in the CNS synapses are mediated by the AMPA-type ionotropic
glutamate receptor (AMPAR), a ligand gated ion channel activated by the neurotransmitter glutamate. The pore
forming subunits of AMPARs (GluA1-4 subunits) assemble as homo- or hetero-tetramers. The native AMPARs
co-assemble with a rich repertoire of transmembrane auxiliary subunits which belong to different protein families,
such as TARP, GSG1L, CNIH, CKAMP, and synDIG. Incorporation of different auxiliary subunit confers AMPAR
with unique ion channel gating kinetics, pharmacology, and in many cases trafficking regulation. The varying
expression patters of auxiliary subunits in brain provides opportunities to produce drugs that target specific
AMPAR auxiliary subunit combinations, which would have improved target specificity and less side effects over
existing ones such as Perampanel (NAM) and ampakines (PAM) that bind to the common pore forming subunits
of AMPARs (GluA1-4). Indeed, several NAMs that are selective to TARP gamma-8 containing AMPARs are
already available and effective in seizures and pain. All the TARPs except for the TARP gamma-2 (encoded by
CACNG2) are understudied and present in Phanos and IDG resource. Among these the biology is least
understood for the type-II TARPs (CACNG5 and 7, which encodes TARP gamma-5 and 7), whose sequences
are distant from the type-I TARPs (CACNG2, 3, 4, and 8, which encodes TARP gamma-2, 3, 4, and 8). Currently,
it is established that type-II TARPs bind to calcium permeable AMPA-Rs (CP-AMPAR) that lacks the GluA2
subunit and regulate their functions. TARP gamma-5 is expressed in the CA2 of hippocampus and Bergmann
glia of cerebellum, whereas TARP gamma-7 is enriched in cerebellar neurons (Purkinje, basket, stellate, granule,
Bergmann glia, and Golgi cells). Consistently, CP-AMPARs were functionally detectable in these cell types. The
function of CP-AMPARs is highly relevant to ischemic brain damages, brain tumors, addiction, fear-conditioning,
and motor function. Compounds that selectively target type-II TARP containing CP-AMPARs are promising
reagents for pharmacological manipulation to study the cellular function of these complexes and may facilitate
the future development of drugs for treating the pathological conditions described above. We hypothesize that
the type-II TARPs operate under different molecular mechanism from type-I TARPs, which do not specialize in
CP-AMPAR modulation. To illuminate the structural basis for the mechanism of type-II TARP function, we
propose to solve the high-resolution structures of a type-II TARP in complex with CP-AMPAR, which is currently
missing. Based on the insights obtained from the structures of other AMPAR/auxiliary subunit complexes we
predict that the differences in sidechain interaction network at the protein interaction interface determine the
types of functional readout of modulation. The outcome of this research is expected to produce high resolution
molecular model of the interaction interfaces between AMPAR and type-II TARP, which in turn would facilitate
further functional research at the molecular level of currently understudied type-II TARPs (i.e. CACNG5 and 7).
Public Health Relevance Statement
Project Narrative
The synaptic ion channels, known as AMPA receptors, are critical for learning, memory,
and cognition, while their dysfunction is related to cognitive decline, intellectual disability,
ischemic brain damages, brain tumors, addiction, and movement disorders. Therefore,
they are considered as effective targets for drugs that could alleviate symptoms of
various neurological and psychiatric disorders, as well as addiction and brain tumors.
We propose to reveal the molecular mechanism of highly relevant but understudied
AMPA receptor auxiliary subunit (CACNG5 and 7) function using cryo-EM and
electrophysiology, which in turn could guide rational design of new therapeutic
compounds.
No Sub Projects information available for 1R03TR004196-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03TR004196-01
Patents
No Patents information available for 1R03TR004196-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03TR004196-01
Clinical Studies
No Clinical Studies information available for 1R03TR004196-01
News and More
Related News Releases
No news release information available for 1R03TR004196-01
History
No Historical information available for 1R03TR004196-01
Similar Projects
No Similar Projects information available for 1R03TR004196-01